| Primary | Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 12 Weeks | Trough FEV1 is measured 10 minutes before drug administration | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0000.081± 0.018
- OG001-0.025± 0.018
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | ANCOVA | ANCOVA model with terms for treatment and center as fixed effects and baseline as a covariate. | <0.0001 | | Mean Difference (Final Values) | 0.106 | | | 2-Sided | 95 | 0.055 | 0.157 | | | | No | Superiority or Other | | |
|
| Primary | Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks | Average hourly FEV1 AUC0-6 minus baseline FEV1 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Trough FEV1 (Forced Expiratory Volume in 1 Second) at 6 Weeks | Trough FEV1 is measured 10 minutes before drug administration | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1 | Average hourly FEV1 AUC0-6 minus baseline FEV1 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Day 1 (after first dose) | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Average Hourly FEV1 AUC0-6 (Area Under the Curve From Zero to Six Hours) at Week 6 | Average hourly FEV1 AUC0-6 minus baseline FEV1 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) on Day 1 | Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 6 | Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FEV1 (Forced Expiratory Volume in 1 Second) at Week 12 | Peak FEV1 is defined as the maximum FEV1 observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Trough FVC (Forced Vital Capacity) at 12 Weeks | Trough FVC is measured 10 minutes before drug administration | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 12 Weeks | Average hourly FVC AUC0-6 minus baseline FVC | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Trough FVC (Forced Vital Capacity) at 6 Weeks | Trough FVC is measured 10 minutes before drug administration | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 6 weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) on Day 1 | Average hourly FVC AUC0-6 minus baseline FVC | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Average Hourly FVC AUC0-6 (Area Under the Curve From Zero to Six Hours) at 6 Weeks | Average hourly FVC AUC0-6 minus baseline FVC | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 6 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FVC (Forced Vital Capacity) on Day 1 | Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Day 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 6 | Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | baseline and 6 Weeks (after first dose) | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Change From Baseline in Peak FVC (Forced Vital Capacity) at Week 12 | Peak FVC is defined as the maximum FVC observed in the first three hours after dose of study medication | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | Baseline and 12 Weeks | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 15 Minutes on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 30 Minutes on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 1 Hour on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 2 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Least Squares Mean | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 3 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 4 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 6 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hours | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at -10 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 10 minutes before dosing | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 15 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 30 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 1 Hour at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 2 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 3 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 4 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 6 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at -10 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 10 minutes before dosing | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 15 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 30 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 1 Hour at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 2 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 3 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 4 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FEV1 at 6 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 15 Minutes on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 30 Minutes on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 1 Hour on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 2 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 3 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 4 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 6 Hours on Day 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at -10 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 10 minutes before dosing | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 15 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 30 Minutes at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 1 Hour at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 2 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 3 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 4 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 6 Hours at Week 6 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at -10 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 10 minutes before dosing | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 15 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 15 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 30 Minutes at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 30 minutes | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 1 Hour at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 1 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 2 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 2 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 3 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 3 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 4 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 4 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | FVC at 6 Hours at Week 12 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters | | 6 hour | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 1 | Puffs of rescue albuterol used during the day in week 1 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 2 | Puffs of rescue albuterol used during the day in week 2 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 3 | Puffs of rescue albuterol used during the day in week 3 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 4 | Puffs of rescue albuterol used during the day in week 4 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 5 | Puffs of rescue albuterol used during the day in week 5 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 5 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 6 | Puffs of rescue albuterol used during the day in week 6 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 7 | Puffs of rescue albuterol used during the day in week 7 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 7 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 8 | Puffs of rescue albuterol used during the day in week 8 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 9 | Puffs of rescue albuterol used during the day in week 9 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 9 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 10 | Puffs of rescue albuterol used during the day in week 10 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 10 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 11 | Puffs of rescue albuterol used during the day in week 11 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 11 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Day Time Albuterol Use During Week 12 | Puffs of rescue albuterol used during the day in week 12 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per day | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 2 | Puffs of rescue albuterol used during the night in week 2 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 3 | Puffs of rescue albuterol used during the night in week 3 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 4 | Puffs of rescue albuterol used during the night in week 4 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 5 | Puffs of rescue albuterol used during the night in week 5 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 5 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 6 | Puffs of rescue albuterol used during the night in week 6 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 7 | Puffs of rescue albuterol used during the night in week 7 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 7 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 8 | Puffs of rescue albuterol used during the night in week 8 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 9 | Puffs of rescue albuterol used during the night in week 9 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 9 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 10 | Puffs of rescue albuterol used during the night in week 10 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 10 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 11 | Puffs of rescue albuterol used during the night in week 11 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 11 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Night Time Albuterol Use During Week 12 | Puffs of rescue albuterol used during the night in week 12 | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Puffs per night | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning Peak Expiratory Flow Rate (PEFR) at Week 1 | | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 2 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 3 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 4 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 5 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 5 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 6 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 7 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 7 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 8 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 9 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 9 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 10 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 10 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 11 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 11 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Morning PEFR at Week 12 | Weekly means for morning PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 1 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 1 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 2 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 3 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 3 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 4 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 5 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 5 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 6 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 7 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 7 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 8 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 9 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 9 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 10 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 10 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 11 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 11 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Evening PEFR at Week 12 | Weekly means for evening PEFR | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Liters/minute | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Patient Global Evaluation | The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to chronic obstructive pulmonary disease (COPD). The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8) | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Units on a scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Patient Global Evaluation | The Patient Global Evaluation reflected the patient's opinion of their overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Units on a scale | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Physician Global Evaluation | The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Units on a scale | | Week 6 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |
| Secondary | Physician Global Evaluation | The Physician Global Evaluation reflected the physician's opinion of the patients overall condition with respect to COPD. The scale responses were: Poor (1,2). Fair (3,4), Good (5,6) and Excellent (7,8). | Participants analyzed belonged to the Full Analysis Set (FAS) and included all patients randomized, treated with study medication and had baseline FEV1 and at least one post-dose trough FEV1. | Posted | | Least Squares Mean | Standard Error | Units on a scale | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Tiotropium | | | OG001 | Combivent (Ipratropium/Albuterol) | 2 actuations 4 times daily |
| |